Skip to content
DataLookout
Menu

CRAFT-WHFNCT06815471

CRF2 Agonist for the Treatment of Worsening Heart Failure

StatusRecruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 6 months later, enrollment reduced 30%.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment reduced: 300 → 210 participants Show 7 more changesShow less
    • Primary and study completion pushed from Dec 2026 to Jul 2027
    • Recruitment resumed after suspension
    • Eligibility criteria expanded, about 63 words
    • Trial arms changed: 4 → 2
    • Site details revised at 55 of 55 sites
    • Publications: details revised at 6 of 6 entries
    • Study description shortened, about 3 words
  2. Stopped Trial status changed: Active, Not Recruiting → Suspended Sponsor's reason: The DSMB recommended pausing the enrollment to give time to the Executive Committee to revise the eligibility criteria to exclude patients who may be in impending cardiogenic shock or in other ways too ill to safely participate in the trial.v8
  3. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 55 of 55 sites
    v7
  4. Minor Trial sites expanded: 43 → 55 locations
    • Study description revised
    v6
  5. Minor Study sites: 16 to 43v5
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Study sites: 10 to 16
    • Publications: details revised at 6 of 6 entries
    v4
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 10
    • Start date changed from estimate of Jul 2025 to Aug 7, 2025
    v3
  3. Notable Primary endpoints revised (5)
    • Start date: Jun 2025 to Jul 2025
    • Interventions: CRF2 agonist (Drug), Placebo (Drug) to COR-1167 (Drug), Placebo (Drug)
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Natriuresis
Timeframe: 24 hours
Body weight
Timeframe: 7 days
NT-proBNP
Timeframe: 7 days
Kansas City Cardiomyopathy Questionnaire (KCCQ)-Total Symptom Score (TSS)
Timeframe: 28 days
Left Atrial Volume index (LAVi)
Timeframe: 2 days

Arms and interventions

COR-1167 low doseExperimental
PlaceboPlacebo comparator

Drugs: COR-1167, Placebo

Sites

55 sites in 8 countries

Georgia 9, Serbia 9, Poland 8, Spain 7, United States 7, Romania 6, Hungary 5, Czechia 4